FHB focuses on the immune system related services and innovative R&D. Our goal is to establish the cell-based immunotherapies for cancers and autoimmune disorders.
FHB sets up a brand new 661 square meters laboratory, which is qualified with Good Tissue Practice and ISO/IEC 17025 of Taiwan Accreditation Foundation (TAF) certificated.
The mission of FHB is to persistently expand the international cooperations, promote the clinical trials and obtain the medical certificate.
FHB provides immunoprofiling, circulating tumor cells testing, regulation of cell therapy contracting immune cell manufacturing, immune cell bank and contracting research organization.
In addition to the general health examination, immunoprofiling is a well testing item to assess the possibility of disease, including cancer or other immune related disease. FHB provides several immune system services and cooperates with medical center, clinic and health care center to carry out the customized immunoprofiling analysis.
FHB has cooperated and proposed autoimmune cell therapy with several medical centers and clinics. Once received the permission of Center for Drug Evaluation (CDE), patients can be conducted the immune cell therapy in the cooperative medical institution.
FHB provides customized services of clinical trial management to satisfy each requirement of specific products, such as document preparation for IND, application of IRB/FDA/TFDA, project management of clinical trials, statistical analysis for experimental data, redaction of clinical reports, and quality control of laboratory etc.
FHB constructs a complete screening platform for circulating tumor cells based on intensive research. We utilize the advanced flow cytometer and epitope-specific monoclonal antibodies to accurately identify circulating tumor cells.
富禾生醫與高雄醫學大學附設中和紀念醫院合作之《特管辦法》細胞治療案，已獲得衛福部核准，得以將自體免疫細胞治療(CIK)，用於實體癌第四期(胃癌及結腸直腸癌)治療。富禾生醫的細胞製備場所符合人體細胞組織優良操作規範(Good Tissue Practice, GTP)，亦獲衛福部認可。
富禾生醫與高雄醫學大學附設中和紀念醫院合作之《特管辦法》細胞治療案，已獲得衛福部核准，得以將自體免疫細胞治療(CIK)，用於實體癌第四期(胃癌及結腸直腸癌)治療。富禾生醫的細胞製備場所符合人體細胞組織優良操作規範(Good Tissue Practice, GTP)，亦獲衛福部認可。
The general manager of FullHope Biomedical Co., Ltd., Dr. Lee, Jan Mou was invited by Foundation of Medical Professionals Alliance in Taiwan as the lecturer on May 2nd 2021. He took ‘’Advance of Current Immunotherapy: Past, Current and Future aspects’’ as the theme for plastic surgery doctors in Ministry of Health and Welfare Shuang-Ho Hospital. […]
The students of International Ph.D. Program for Cell Therapy and Regeneration Medicine (IPCTRM) at Taipei Medical University (TMU) visited the laboratory of FHB on Apr. 14th 2021. With the industry-academia cooperation, hoping the students had deeply understood the working space in regeneration medicine industry.
The general manager of FullHope, Co., Ltd., Dr. Lee was invited as a special lecturer by Taiwan Academy of Allergy Asthma and Clinical immunology (TAAACI) for the course of immune cell therapy on Mar. 7th 2021. Dr. Lee took “Advance of Current Immunotherapy: Past, Current and future aspects” as theme to explain profound theories in […]
